US 12,133,843 B2
IL-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
Laura Brandolini, L'Aquila (IT); Marcello Allegretti, Rome (IT); and Mauro Martins Teixeira, Belo Horizonte (BR)
Assigned to DOMPÉ FARMACEUTICI S.P.A., Milan (IT)
Appl. No. 16/616,108
Filed by DOMPÉ FARMACEUTICI S.P.A., Milan (IT)
PCT Filed May 28, 2018, PCT No. PCT/EP2018/063929
§ 371(c)(1), (2) Date Nov. 22, 2019,
PCT Pub. No. WO2018/219865, PCT Pub. Date Dec. 6, 2018.
Claims priority of application No. 17173515 (EP), filed on May 30, 2017.
Prior Publication US 2020/0101046 A1, Apr. 2, 2020
Int. Cl. A61K 31/427 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/427 (2013.01) [A61P 31/04 (2018.01)] 6 Claims
 
1. A method of treating secondary pneumococcal infections associated with a preceding influenza infection, in a subject in need thereof, comprising administration of an effective amount of an IL-8 inhibitor, wherein the IL-8 inhibitor is a 2-phenyl-propionic acid derivative of formula (II)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R4 is linear or branched C1-C6 alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy;
R5 is H or linear or branched C1-C3 alkyl; and
R6 is linear or branched C1-C6 alkyl or trifluoromethyl, and wherein the IL-8 inhibitor is administered alone or in combination with one or more pharmaceutically acceptable excipients and/or diluents.